Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
Cardiol Therapeutics received over USD $7 million in proceeds from the exercise of outstanding common share purchase warrants, which the company says extends its cash runway into H1 2028. The capital funds operations through the topline data readout from the pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and supports regulatory preparations for a potential New Drug Application, subject to favorable trial results and regulatory input.
Key figures
- Cash runway
- extended into H1 2028
- Pivotal trial
- Phase III MAVERIC (NCT06708299) of CardiolRx in recurrent pericarditis
- Warrant early expiry
- October 16, 2026, 4:00 p.m. ET
- Warrant issuance dates
- ["2025-10-17","2025-10-20"]
- Warrant exercise proceeds
- over USD $7 million
- Warrants originally issued
- 5712500
- Warrants unexercised as of 2026 09 15
- 425000
- Remaining warrant potential proceeds usd
- 573750
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.